Trial Profile
Efficacy and tolerability of ferric carboxymaltose in cancer patients with iron deficiency anemia: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2016
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Adverse reactions; Therapeutic Use
- 13 Jul 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology